There are currently several new treatments in development for Thyroid Eye Disease (TED). We hope that these will translate into medicines that are available to patients in the near future.

Clinical trials testing these treatments are being set up throughout the UK and some centres are looking to recruit patients who may be eligible to participate in their studies. If you would like to find out whether you are eligible to take part in any of the trials advertised on this page, please contact the individual study sites or discuss with your healthcare team. The BTF does not receive funding for putting details of these trials on our website. 

Are you a researcher or clinician running a TED clinical trial in your hospital? To share details about your study with patients who may be eligible for recruitment, please email [email protected]

Viridian

Viridian is studying multiple potential new treatment options in clinical trials for people living with thyroid eye disease (TED). All of Viridian's clinical trials are fully enrolled, therefore no longer seeking additional participants. For more information on these trials, please follow the links below or speak to your doctor.  

Safety and Tolerability Study of VRDN-003 in Participants with TED

Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants with TED

Efgartigimod

This Phase 3 clinical trial was running in several UK centres but it closed to recruitment in December 2025.  

Find out about trial recruitment centres

Batoclimab

This Phase 3 clinical trial is now "completed" which means that the study has ended and participants are no longer being examined or treated. Further information about the results of this study will be shared when it is available.

Study to assess Batoclimab in participants with active TED